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INTRODUCTION
Cholangiocarcinoma is a malignancy arising from the
epithelial cells of the bile duct or gallbladder. Although it
occurs with greater frequency in Asian countries, its incidence
has been steadily increased in U.S.A. and Europe over the
past three decades (1, 2). Surgery still remains the only cura-
tive treatment, but many of these tumors are not resectable
at the time of diagnosis. Chemotherapy and radiation thera-
py have been of limited value (1). A variety of biological
response modifiers, including cytokines and bacterial prod-
ucts, have been employed in immunochemotherapy of vari-
ous cancers. High dose Interleukin (IL)-2 has been tested
against various malignant tumors, both in experimental mod-
els and in clinical studies, but its effectiveness has been ham-
pered by undesirable side effects (3).
EC-18 is a monoacetyldiglyceride (EC-18 specifically, 1-
palmitoyl-2-linoleoyl-3-acetyl-rac-glycerol) that occurs nat-
urally in various seed oils, in bovine udder and in milk fat,
and has been isolated from the antlers of sika deer (Cervus
nippon TEMMENICK); these antlers have been used as a ton-
ics in oriental medicine. We have shown that chemically
synthesized EC-18 can stimulate the proliferation of hemato-
poietic stem cells, bone marrow stromal cells (4, 5), and
immune system cells, including T and B lymphocytes, den-
dritic cells (DCs) and macrophages, both in vivo and in vitro.
Using the Syrian golden hamster model of biliary cancer, we
observed previously that IL-2 encoded bone marrow stromal
cells (ad/hIL-2 BMSC) suppressed metastatic tumor (6).
EC-18 was an effective agent as in inhibiting the growth of
metastatic biliary cancer.
Toll-like receptors (TLRs), especially TLR-4, has been shown
to be important in both innate and adaptive immunity to
various cancers. Activation of TLR-4 in tumor cells was found
to stimulate cancer cell proliferation, whereas inhibition of
TLR-4 signaling retarded tumor growth and prolonged the
survival of tumor bearing mice (7). EC-18 has been shown to
have inhibitory effects on TLR-4 expression of experimental
biliary cancer cells (KIGB-5). 
We report here the use of a novel agent of EC-18 as metas-
tasis inhibiting agent in hamster biliary cancer model (KIGB-
5). This suppression of metastasis is likely through stimula-
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EC-18, a Synthetic Monoacetyldiacylglyceride, Inhibits Hematogenous
Metastasis of KIGB-5 Biliary Cancer Cell in Hamster Model
EC-18 (monoacetyldiacylglyceride) stimulates T cell production of IL-2, IL-4, IL-12,
IFN-γ , and GM-CSF in vitro. To study the effects of these cytokines stimulated by
EC-18 on cancer cells, we applied hamster biliary cancer model, a difficult cancer
to treat. Cancer (KIGB-5) cells were given intravenously to produce hematogenous
metastatic lung lesions which were treated with EC-18 at 10, 25, and 50 mg/kg/day
respectively. The fourth group was untreated control. At 4th, 8th, and 12th week the
lungs were examined. EC-18 treated groups showed only a few microscopic lung
lesions and no evidence of metastatic lesion with highest dose whereas widespread
gross lung lesions were observed in untreated control. To investigate whether the
anti-tumor effect of EC-18 is associated with suppression of tumor cell Toll-like recep-
tor 4 (TLR-4) expression in addition to stimulation of the immune cells, KIGB-5 cells
were exposed to LPS with or without EC-18. TLR-4 mRNA and protein expression,
measured by reverse transcriptase PCR (RT-PCR), real-time quantitative PCR and
western blot analysis, showed suppression of TLR-4 expression in KIGB-5 cells
treated with EC-18 compared with control. In conclusion, EC-18 has a significant
anti-tumor effect in this experimental model of biliary cancer suggesting potential
for clinical application to this difficult cancer.
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tion of immune cells (T & B cells, DC & macrophages) in
association with suppression of tumor cell TLR-4 expression.
MATERIALS AND METHODS
Animals and cell lines
Female Syrian golden hamsters (6-8 weeks old) were pur-
chased from Harlan (Indianapolis, IN, U.S.A.) and housed
in the specific pathogen free unit (temperature, 22±2℃;
humidity 60±4%, 12 hr light/dark cycle) at the Animal Re-
source Center at the Asan Institute for Life Science. Water
was provided ad libitum. All animals used in this experiment
were cared for and used humanely according to the NIH Prin-
ciples of Laboratory Animal Care (U.S. NIH publication No.
85-23, Revised 1985) and the guidelines for animal experi-
ments of the Asan Institute for Life Sciences and Technolo-
gy. The Syrian golden hamster cholangiocarcinoma cell line,
KIGB-5, was cultured in complete RPMI-1640 medium
(GIBCO BRL, Grand Island, NY, U.S.A.) supplemented with
10% fetal bovine serum (FBS) (GIBCO BRL).
EC-18
EC-18 was synthesized by the patented process (8) (Kore-
an patent appl. 10-2005-0065792 [2005.7.20]) from 1-palmi-
toylglycerol as a starting material. 
The purity of EC-18 in this paper was determined above
99% using HPLC method (Instrument: Younlin Solvent
Delivery Pump M930, Younlin UV Absorbance Detector
M720; Column: YMC-pack ODS-A A-303 250×4.6 mm
I.D., S-5M, 12 nm; Detector: 205 nm; Mobile phase: Iso-
propanol: Acetonitrile=45:55; Temperature: 25℃, Flow rate:
1 mL/min).
T cell proliferation assay
Splenocytes were collected by flushing the spleen of mice
and single cell suspensions were obtained by repeated aspi-
ration and flushing. Cell preparation was suspended in Iscove’s
modified Dulbecco’s medium (IMDM, GIBCO) supplement-
ed with 10% FBS, with 5×10
4 viable cells per well cultured
for 5 days with EC-18 0.01, 0.1, and 1 μ g/mL or rm IL-2
10, 20 ng/mL, each in triplicates. On day 4, 1 μ Ci 
3H-thymi-
dine was added to each well, and the cells were cultured for
an additional 18 hr. On day 5, the cells were harvested and 
3H-
thymidine incorporation was measured. Stimulation index
(SI) was calculated as CPM in sample/CPM in control.
Elispot assay of T cells
T4 and T8 cells were purified using magnetic beads, goat
anti-mouse CD4 and CD8, respectively (MACS bead, Mil-
tenvi Biotec, Bergich Gladbach, Germany), and anti-goat
IgG. Each T cell preparation was suspended in Iscove’s mod-
ified Dulbecco’s medium (IMDM, GIBCO) supplemented
with 10% FBS, with 2×10
6 viable cells per well cultured
for 5 days with EC-18 0.01, 0.1, and 1 μ g/mL or rm IL-2 10,
20 ng/mL. The number of IL-2 producing cells was counted
using rm IL-2 Elispot system kit (AID, Strasburg, Germany)
according to the manufacturer’s instruction.
Measurement of cytokine secretion
Anti-CD3 monoclonal antibody (Pharmingen, Hamburg,
Germany) was coated onto 96-well plates. T cells were seed-
ed at 2×10
5 viable T cells per well and cultured with 5 μ g/
mL anti-CD28 MoAb (Pharmingen). EC-18 was added to the
culture media at 0.1 or 1.0 μ g/mL, with no EC-18 as control,
and the culture media were harvested on day 5. The superna-
tants were obtained by centrifugation, and the concentrations
of secreted cytokines were quantified using a Bio-plex kit (Bio-
rad, Washington, DC, U.S.A.) according to the manufactur-
er’s instruction.
Measurement of [Ca
2+]i influx by flowcytometry
Hamster was treated with EC-18 50 mg/kg/day orally for
2 weeks and then splenocytes were harvested from control
and EC-18 treated group. Measurement of Calcium ion was
performed at day 1. An increase in [Ca
2+]i was directly mea-
sured in splenocytes by change in the fluorescence intensity
of fluo-3 AM (Molecular Probe, Inc., Eugene, OR, U.S.A.)
loaded cells. Cells (5×10
6/mL) were incubated with HBSS
buffer (Hank’s balanced salt solution without Ca
2+, Mg
2+) con-
taining 4 μ M Fluo-3AM and 0.02% Pluonic F-127 (Molec-
ular Probe, Inc.) in DMSO for 30 min at 37℃, Cells were
then washed twice with HBSS buffer and resuspended with
5 mM Calcium chloride containing HBSS buffer. We followed
changes in [Ca
2+]i for a period of 0-120 sec after stimulation
of splenocytes with 5 mM Ionomycin. Analysis was performed
on the flowcytometry equipped with the 525 nm.
Cytotoxic T Lymphocytes (CTL) Assay
Hamsters were injected in their livers with 1×10
5 KIGB-
5 cells and treated with 50 mg/kg/day EC-18 or PBS (con-
trol). After 8 weeks, when liver tumors had developed, spleno-
cytes were obtained from tumor bearing hamsters. Cytotoxic
activity was measured by incubating splenocytes with 2×10
4
target KIGB-5 cells, which had been labeled with 
51Cr for 2
hr and washed three times, at a splenocyte: target cell ratio of
25:1, in 96-well round bottom plates in triplicate. After incu-
bation for 4 hr at 37℃, the supernatants were harvested, and
the amount of 
51Cr released was measured with a Packard Par-
ias gamma spectrometer (Packard Instrument, Meridian, CT,
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and the percentage of specific 
51Cr release was calculated as:
Percent specific cytotoxicity=(Specific release-spontaneous
release)÷(maximum release-spontaneous release)×100.
RT-PCR analysis of TLR-4
KIGB-5 cells were exposed in vitro with 10 μ g/mL lipo-
polysaccharide (LPS) and/or 1 μ g/mL EC-18 and the cells were
harvested. Total RNA was isolated using RNeasy kits (Qia-
gen) and reverse transcribed with Superscript I (Life Technolo-
gies) and random hexamers. The polymerase chain reaction
was performed using Taq DNA polymerase (Takara, Tokyo,
Japan) and primers specific for hamster TLR-4 (forward: 5′ -
GCAGGAACACCTACCTAGA-3′ ; reverse, 5′ -GCTTGAT
ACAGTAGGAGCTG-3′ ; product size, 402 bp) and glyceral-
dehyde-3-phosphate dehydrogenase (GAPDH; forward, 5′ -
GTGGAGATTGTTGCCATCAACG-3′ ; reverse, 5′ -CAGTG
GATGCAGGGATGATGTTCTG-3′ ; product size, 507 bp)
as the endogenous control. Amplification conditions consist-
ed of 30 cycles of denaturation at 95℃ for 30 sec, annealing
at 52℃for 30 sec, and extension at 72℃for 40 sec. The PCR
products were electrophoresed on 2% agarose gels, which were
stained with ethidium bromide for visualization.
Real-time quantitative PCR analysis of TLR-4
Real-time quantitative PCR was performed in triplicate in
384-well plates; each 20 μ L reaction consisted of 10 μ L of
SYBR Green Master Mix (Applied Biosystems Foster City,
CA, U.S.A.), 0.8 μ Lof 10 pM/μ Lforward and reverses primers
of hamster TLR-4 and GAPDH. 50℃ for 2 min and 95℃
for 10 min followed by 40 cycles of 95℃for 30 sec and 60℃
for 30 sec, 72℃ for 30 sec. The sequences of the primers de-
signed to span within hamster TLR-4 (forward primer: GCA-
TGGCCTTCCGTGTTCCTA, reverse primer: CTTCAGT-
GGGCCCTCAGATGC). The real-time PCR analysis was
performed on a Prism 7900 Sequence Detection System (Ap-
plied Biosystems).
Western blot analysis of TLR-4
Western blot analysis was conducted as previously described
(9). Primary antibody to rabbit serum anti-mouse Toll-like
receptor (TLR-4, 1:1,000 dilution, Ebioscience, San Diego,
CA, U.S.A.) was applied overnight at 4℃Secondary antibody
conjugated to horseradish peroxidase was applied the follow-
ing day, followed by detection using enhanced chemilumi-
nescence(ECL) (Amersham Biosciences, Little Chalfort, U.K.).
The same blots were also probed with a monoclonal anti-
body β -actin (1:500, Biolegend, San Diego, CA, U.S.A.) to
verify equal protein loading in all lanes. Band densities were
quantified by means of a Bio-Rad Versa Doc Imaging System
(Bio-Rad, Washington, DC, U.S.A.).
In vivo experimental protocol
Each of 20 hamsters was injected in the femoral vein with
5×10
5 KIGB-5 cells in 100 μ L of serum free RPMI 1640.
The hamsters were divided into 4 groups of 5 each: The con-
trol group was treated only with RPMI. The remaining 3
groups were administered 10, 25, and 50 mg/kg body weight/
day of oral EC-18, 2 weeks on and 1 week off for 12 weeks.
On the 4th week, one animal from each group was sacrificed
and two animals from each group were sacrificed at the 8th
and 12th week for pathological examination. And their liv-
ers and lungs were removed, fixed in formalin, stained with
hematoxylin and eosin, and examined by light microscopy.
Statistical analysis
Data were analyzed by ANOVA. P≤0.05 was considered
statistically significant. All data are expressed as mean±
S.E.M.
RESULTS
T cell proliferation assay
The effects of EC-18 on T-cell proliferation were tested by
3H-thymidine uptake. Cells treated with EC-18 1 μ g/mL sho-
wed a 2.13 fold increase in 
3H-thymidine uptake compared
with control untreated cell (P<0.005). EC-18 0.1 μ g/mL treat-
ed cells were also increased 2.07 fold compared with control
cells (P<0.05). Cells treated with IL-2 20 ng/mL showed a
2.02 fold increase compare with control untreated cells (P<
0.05). Cells treated with 0.01, 0.1, and 1 μ g/mL of EC-18
were stimulated in dose dependent manner (Table1).
IL-2 secretion by EC-18 treated T cells
Following 5 days in culture with EC-18 1 μ g/mL, the num-
ber of IL-2 producing cells was counted AID Elispot Reader
System. The number of IL-2 producing T4 cells was increas-
ed 1.52-fold with EC-18 treatment which was statistically
significant (P<0.05). The difference in the number of IL-2
producing T8 cells was not statistically significant (P<0.26)
*P<0.05, 
� P<0.005.
CPM of Control: 154.56±19.74.
Condition Stimulation index (±S.E.M)
IL-2 (10 ng/mL) 1.75±0.38*
IL-2 (20 ng/mL)  2.02±0.29*
EC-18 (0.01 μ g/mL) 1.92±0.49
EC-18 (0.1 μ g/mL) 2.07±0.36*
EC-18 (1 μ g/mL) 2.13±0.31
�
Table 1. Stimulation index in T cell proliferation assay (n=9 in each
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(Fig. 1).
Secretion of cytokines by EC-18 treated T cells
Cytokine secretion was measured by using Bio-plex. As
shown in Fig. 2, the secretions of IL-2 and IL-4 were much
higher in EC-18 treated group than in the control (P<0.05
and P<0.005 respectively). The secretions of IL-12, GM-CSF
and IFN-γ were also increased in EC-18 treated group com-
pared with control (P<0.05).
Measurement of [Ca
2+]i influx of EC-18
EC-18 treated splenocytes showed 2.9 times increased [Ca
2+]i
influx than control (Fig. 3). 
Cytolytic activity of T cells from EC-18 treated hamsters
Cytolytic activity of T cells was measured by 
51Cr release
from pre-labeled tumor cells. At a T-cell to target cell ratio
of 100:1, specific cytolysis was 19.5±0.37% in EC-18 treat-
ed cells compared with 13.7±0.19% in untreated control
cells (P<0.05), and at a 25:1 ratio, it was 16.6±0.28% in
EC-18 treated cells compared with 5.1±0.10% in untreat-
ed control cells (P<0.005). 
TLR-4 mRNA expressions of LPS stimulated biliary 
cancer cells with and without EC-18
The expression of TLR-4 mRNA was assayed by reverse
transcriptase PCR (RT-PCR) and real-time quantitative PCR
on KIGB-5 cells which were untreated control, treated with
LPS (10 μ g/mL) only, EC-18 (1 μ g/mL) only and LPS with
EC-18 treatment group. Treatment of KIGB-5 cells with
EC-18 (1 μ g/mL) reduced the expression of TLR-4 mRNA
when compared with untreated control and LPS (10 μ g/mL)
treated cells (Table 2, Fig. 4).
TLR-4 protein expressions of LPS stimulated biliary 
cancer cells with and without EC-18
We examined the levels of TLR-4 in KIGB-5 cells which
were untreated control, treated with LPS (10 μ g/mL) only, EC-
18 (1 μ g/mL) only and LPS with EC-18 treatment group by
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Fig. 1. IL-2 secretion by 1-palmitoyl-2-linoleoyl-3-acetyl-rac-glyc-
erol (EC-18) treated T-cells. Brown spots indicate IL-2 producing
cells. Data are expressed as mean±S.E.M. *P<0.05 compared
with the control group.
Fig. 2. Cytokine secretion by EC-18 treated T cells compared with
Anti-CD3+Anti-CD28 treated control (IL-2, IL-4, IL-12[p70], GM-CSF,
IFN-γ and TNF-α ). 
*P<0.05, 
� P<0.005 compared with the control group.
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Fig. 3. Effect of EC-18 on [Ca
2+]i of mouse lymphocyte after Iono-
mycin exposure. Change in [Ca
2+]i was compared with EC-18
treated group and control group for a period of 0-120 sec after expo-
sure of Ca
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western blot analysis. Treatment of KIGB-5 cells with EC-
18 (1 μ g/mL) reduced the level of TLR-4 protein when com-
pared with untreated control and LPS (10 μ g/mL) treated cells
(Fig. 5).
Pathology of metastatic biliary cancer in the lungs
At the 4th week, all experimental groups showed no evi-
dence of disease in the lungs, except a single microscopic
lesion in control group and EC-18 10 mg/kg/day treated
group. At the 8th week, animals in the control group showed
widespread metastases in the both lungs. Group treated with
10, 25, and 50 mg/kg/day EC-18 showed no gross tumor,
but microscopic examination revealed 2 microscopic lesions
in 10 mg/kg/day group, 1 microscopic lesion in 25 mg/kg/day
group and no microscopic lesions in 50 mg/kg/day group in
the lungs (Table 3, Fig. 6).
R2 of TLR-4: 0.9754, R2 of GAPDH: 0.9959.
Control: KIGB-5 cells were exposed medium alone. LPS: KIGB-5 cells
were exposed LPS (10 μ g/mL). EC-18: KIGB-5 cells were exposed EC-
18 (1 μ g/mL). LPS+EC-18: KIGB-5 cells were exposed LPS (10 μ g/mL)
and EC-18 (1 μ g/mL).
Data are expressed as mean±S.E.M of triplicate of reactions. 
*P<0.005 compared with the LPS and EC-18 or LPS+ EC-18.
TLR-4 GAPDH TLR-4/GAPDH
Control 0.9879±0.0344 1.0962±0.0235 0.9012±0.0314
LPS 1.3604±0.0381 1.0618±0.0322 1.2812±0.0359
(10 μ g/mL)
EC-18 0.9228±0.0556 1.0821±0.0318 0.8528±0.0514* 
(1 μ g/mL)
LPS+EC-18 1.0610±0.0349 1.0667±0.0293 0.9947±0.0327* 
Table 2. TLR-4 real-time quantitative PCR analysis in KIGB-5 cells
(biliary cancer cell line)
Hamster TLR-4
1
mGAPDH
2 3 4
Fig. 4. Expression of TLR-4 in KIGB-5 cells by RT-PCR. EC-18 in-
hibits TLR-4 expression by RT-PCR in KIGB-5 cells. Line 1: Control:
KIGB-5 were exposed medium alone, 2: LPS: KIGB-5 were ex-
posed LPS (10 μ g/mL), 3: EC-18: KIGB-5 were exposed EC-18
(1 μ g/mL), 4: LPS + EC-18: KIGB-5 were exposed LPS and EC-18.
Control
EC-18 EC-18 EC-18
(RPMI)
(10 mg/ (25 mg/  (50 mg/
kg/day) kg/day) kg/day)
Tumor size of pulmonary metastatic lesions
Time
obser- Hamster
ved group
4th week A 1; <1 mm 1; <1 mm 0 0
8th week B 1; <1 mm 1; <1 mm 1; <1 mm 0
C 11; <1 mm 1; <1 mm 0 0
1; >1 mm
12th week D 23; <1 mm 0 0 0
2; >1 mm
E 55; <1 mm 0 0 0
25; >mm
Table 3. Tumor size of pulmonary metastatic lesions in different
dose of EC-18
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*
Fig. 5. Expression of TLR-4 in KIGB-5 cells by western blot analy-
sis. EC-18 (1 μ g/mL) treated cells reduced the level of TLR-4 pro-
tein when compared with untreated control and LPS (10 μ g/mL)
treated cells. Lane 1, Control: KIGB-5 were exposed medium alone;
2, LPS: KIGB-5 were exposed LPS (10 μ g/mL); 3, EC-18: KIGB-5
were exposed EC-18 (1 μ g/mL); 4, LPS+EC-18: KIGB-5 were ex-
posed LPS and EC-18. Band densities were quantified by means
of a Bio-Rad Versa Doc Imaging System. *P<0.05 compared with
the control group (n=3).
Fig. 6. Microscopic findings (H&E, ×100) of the lungs at 8 week
after injection of KIGB-5 cells. (A) Control hamsters, (B) hamsters
treated with EC-18 10 mg/kg/day, (C) EC-18 25 mg/kg/day, (D)
EC-18 50 mg/kg/day. Control group showed multiple metastatic
lesions. Hamster groups treated with EC-18 10, 25 mg/kg/day in
respect showed metastatic lesions, except EC-18 50 mg/kg/day
treated group which showed no evidence of the lesion.
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At the 12th week, both animals in the control group had
numerous conglomerated lesions in the lungs. In contrast,
animals in EC-18 treated groups had no evidence of gross
tumors. Animals treated with EC-18 (50 mg/kg/day) showed
no evidence of metastatic lesions throughout the experimen-
tal period (Table 3, Fig. 7).
DISCUSSION
We previously reported that the water extracts from deer
antler, Cervus nippon, had a stimulating effects on hemato-
poiesis in vitro and in vivo (4, 5), and we subsequently demo-
nstrated that monoacetyldiglyceride (EC-18) was the com-
ponent with the most potent stimulatory activity on the bone
marrow stem cells, bone marrow stromal cells and immune
cells.
In this paper, we showed that EC-18 has a potent anti-tumor
activity in experizmental hematogenous metastatic biliary
cancer in Syrian golden hamsters. We found that EC-18 stim-
ulated the activity of CD4
+, CD8
+ cells and macrophages. 
EC-18 treated CD4
+ and CD8
+ cells in vitro stimulate
the production of cytokines; IL-2, IL-4, IL-12, IFN-γ , and
GMCSF (Fig. 2). These cytokines enhance the cytolytic activ-
ity of NK cells and LAK-like lymphocytes (10-12), and tumor
suppressor function of immune system is critically depen-
dent on the action of IFN-γ and IL-12 (13, 14). The increased
secretion of these cytokines may inhibit tumor growth and
metastasis in this experiment.
In an attempt to understand the mechanism of action of
EC-18 on the immune cells, we studied Ca
2+ influx into lym-
phocytes. EC-18 treatment increases Ca
2+ influx into lympho-
cytes (Fig. 3). Ca
2+ is an essential component of signal trans-
duction in lymphocytes (15, 16). We speculate that the pro-
liferation of T cells, its differentiation to effector T cells, and
the secretion of various cytokines we observed are mediated
by the increase in the cytosolic (Ca
2+) through canonical tran-
sient receptor potential channels (TRPC) activated by phos-
pholipase C (PLC) coupled receptor. PLC in turn generates
DAG by phosphoinositide cascade, and DAG activates protein
kinase C (PKC) which modulates expressions of relevant genes
(17, 19). 
EC-18 has been shown to stimulate Ca
2+ influx into rat
pancreatic acinar cells (18). Long-chain diacylglycerols are,
however, known to be impermeable to cells (19) and metabol-
ically stable in the extracellular fluid. Therefore it is likely
that the action of EC-18 on T cells is mediated through its
interaction with the lymphocyte cell membrane. The exact
mechanism of action of EC-18 needs to be elucidated.
Previously we reported that IL-2 gene-encoded stromal cells
inhibited the growth and metastasis of cholangiocarcinoma
(6). This immuno-cell therapy with ad/hIL-2 encoded stro-
mal cells could be a promising therapeutic alternative as adop-
tive immunocell therapy for biliary cancers (6).
We tested the effects of EC-18 on Toll-like receptor 4
(TLR-4) mRNA and protein expression in KIGB-5 biliary
cancer cells. EC-18 inhibited TLR-4 mRNA and protein
expression in KIGB-5 cells. 
TLR-4 is transmembrane proteins and represents newly
recognized family of vertebrate pattern recognition receptors
in innate immune system. Engagement of TLR-4 by one of
its ligand triggers an intracellular signaling cascade that in-
cludes activation of latent cytoplasmic transcription factor
NF-κ B with it’s translocation to the nucleus and activation
A
a
B
b
C
c
D
d
Fig. 7. Gross pathological and microscopic findings (H&E, ×100) of the lungs at 12 weeks after injection of KIGB-5 cells. (A, a) Control
hamsters, (B, b) hamsters treated with EC-18 10 mg/kg/day, (C, c) EC-18 25 mg/kg/day, (D, d) EC-18 50 mg/kg/day. Control group showed
multiple metastatic lesions whereas, EC-18 10, 25, and 50 mg/kg/day treated group showed no evidence of the lesion.480 M.-H. Kim, H.M. Chang, T.W. Kim, et al.
of MAP kinase (20). LPS derived from Gram negative bac-
teria (endotoxin) is a ligand of TLR-4. Bacterial LPS-bound
TLR-4 strongly stimulates innate immune responses that
enhance killing of bacteria, but it may also cause significant
pathological changes in the host. TLR-4 activation in tumor
enhances immunosuppression in vitro, and escape of tumor
cells from NK cell attack is also TLR-4 dependent (20). TLR-
4 thus has dual effects on the immune system of tumor bear-
ing animals. Toll-like receptors may initially play a critical
role in both innate and adaptive immune response and an
important role in immunity against various cancers. Activa-
tion of TLR-4 in tumor cells stimulates proliferation of can-
cer cells, while the blockade of TLR-4 signaling retards tumor
growth and prolongs the survival of tumor bearing mice.
Taken together, these findings indicate that TLR signaling
induces a cascade that can lead to tumor evasion of immune
surveillance.
We speculate that the observed inhibition of TLR-4 by EC-
18 may have contributed to the retardation of tumor growth
and metastasis in tumor bearing hamsters. These findings
suggest that EC-18 may have positive therapeutic potentials
in the treatment of biliary cancer.
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